Self-Assembling Nanoparticles Containing Dexamethasone as a Novel Therapy in Allergic Airways Inflammation

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kenyon, Nicholas J ^a   Bratt, Jennifer M ^a   Lee, Joyce ^a   Luo, Juntao ^a,b   Franzi, Lisa M ^a   Zeki, Amir A ^a   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOCARRIER; NANOPARTICLE; OVALBUMIN;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EOSINOPHIL; LUNG LAVAGE; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; RESPIRATORY TRACT ALLERGY;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINE CCL2; DEXAMETHASONE; DISEASE MODELS, ANIMAL; INTERLEUKIN-4; LUNG; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NITRIC OXIDE; OVALBUMIN; PNEUMONIA;

EID: 84886423792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077730     Document Type: Article

References (36)

1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, et al. (2009) An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180: 59-99.
2. Wenzel SE, Busse WW (2007) Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 119: 14-21; quiz 22-13.
3. McFadden ER Jr, (2003) Acute severe asthma. Am J Respir Crit Care Med 168: 740-759.
4. McGeehan M, Busse WW, (2002) Refractory asthma. Med Clin North Am 86: 1073-1090.
5. Kenyon NJ, Liu R, O'Roark EM, Huang W, Peng L, et al. (2009) An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 603: 138-146.
6. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, et al. (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30: 6006-6016.
7. Jackson JK, Zhang X, Llewellen S, Hunter WL, Burt HM, (2004) The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm 270: 185-198.
8. Xiao K, Luo J, Li Y, Lee JS, Fung G, et al. (2011) PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release 155: 272-281.
9. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK, (1998) An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 53: 849-856.
10. Kenyon NJ, Ward RW, Last JA, (2003) Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 186: 90-100.
11. Silkoff PE, Stevens A, Pak J, Bucher-Bartelson B, Martin RJ, (1999) A method for the standardized offline collection of exhaled nitric oxide. Chest 116: 754-759.
12. Xiao K, Li Y, Luo J, Lee JS, Xiao W, et al. (2011) The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32: 3435-3446.
13. Bratt JM, Franzi LM, Linderholm AL, O'Roark EM, Kenyon NJ, et al. (2010) Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol 242: 1-8.
14. Zeki AA, Franzi L, Last J, Kenyon NJ, (2009) Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180: 731-740.
15. Kenyon NJ, Bratt JM, Linderholm AL, Last MS, Last JA, (2008) Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences. Toxicol Appl Pharmacol 230: 269-275.
16. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, et al. (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184: 602-615.
17. Georen SK, Tcacencu I, Wikstrom AC, Stierna P, (2009) Early timing of low-dose dexamethasone decreases inflammation in a murine model of eosinophilic airway disease. Acta Otolaryngol 129: 182-189.
18. Korideck H, Peterson JD, (2009) Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. J Pharmacol Exp Ther 329: 882-889.
19. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, et al. (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181: 788-796.
20. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, et al. (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365: 1088-1098.
21. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, et al. (1999) Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160: 1816-1823.
22. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, et al. (1992) IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 148: 1086-1092.
23. Chatila TA, Li N, Garcia-Lloret M, Kim HJ, Nel AE (2008) T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. J Allergy Clin Immunol 121: 812-823; quiz 824-815.
24. Lewis CC, Aronow B, Hutton J, Santeliz J, Dienger K, et al. (2009) Unique and overlapping gene expression patterns driven by IL-4 and IL-13 in the mouse lung. J Allergy Clin Immunol 123: 795-804 e798.
25. Sanchez-Moreno P, Boulaiz H, Ortega-Vinuesa JL, Peula-Garcia JM, Aranega A, (2012) Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells. Int J Mol Sci 13: 4906-4919.
26. Sahib MN, Abdulameer SA, Darwis Y, Peh KK, Tan YT, (2012) Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations. Drug Des Devel Ther 6: 29-42.
27. Craparo EF, Bondi ML, Pitarresi G, Cavallaro G, (2011) Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther 17: 670-677.
28. Lim SB, Banerjee A, Onyuksel H (2012) Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release.
29. Noel A, Maghni K, Cloutier Y, Dion C, Wilkinson KJ, et al. (2012) Effects of inhaled nano-TiO(2) aerosols showing two distinct agglomeration states on rat lungs. Toxicol Lett.
30. Raemy DO, Grass RN, Stark WJ, Schumacher CM, Clift MJ, et al. (2012) Effects of flame made zinc oxide particles in human lung cells- a comparison of aerosol and suspension exposures. Part Fibre Toxicol 9: 33.
31. Barlow PG, Brown DM, Donaldson K, MacCallum J, Stone V, (2008) Reduced alveolar macrophage migration induced by acute ambient particle (PM10) exposure. Cell Biol Toxicol 24: 243-252.
32. Warheit DB, Hansen JF, Yuen IS, Kelly DP, Snajdr SI, et al. (1997) Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol Appl Pharmacol 145: 10-22.
33. Wegesser TC, Last JA, (2008) Lung response to coarse PM: bioassay in mice. Toxicol Appl Pharmacol 230: 159-166.
34. Franzi LM, Bratt JM, Williams KM, Last JA, (2011) Why is particulate matter produced by wildfires toxic to lung macrophages? Toxicol Appl Pharmacol 257: 182-188.
35. Chirino YI, Sanchez-Perez Y, Osornio-Vargas AR, Morales-Barcenas R, Gutierrez-Ruiz MC, et al. (2010) PM(10) impairs the antioxidant defense system and exacerbates oxidative stress driven cell death. Toxicol Lett 193: 209-216.
36. Peng L, Liu R, Marik J, Wang X, Takada Y, et al. (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2: 381-389.